GSK, Abbott stand to lose most with India price moves; TPG wraps $1.9B Par Pharma buyout;

@FiercePharma: In Europe, J&J's injectable wins approval and  gets AML-in-elderly use. More | Follow @FiercePharma

> TPG Capital wrapped up its $1.9 billion acquisition of generics maker Par Pharmaceutical, taking the company private. Report

> GlaxoSmithKline ($GSK), Abbott Laboratories ($ABT) and India's Cipla stand to lose most from a newly proposed pricing policy in India, analysts said. Report

> India's Lupin is aiming to boost Japanese sales to $500 million over the next 5 years, twice as much as this year. Report

> Executive compensation grew at Indian drugmakers despite stagnant profits and growth at some companies, Hindu Business Line says. Report

> Daiichi Sankyo plans to merge three supply chain subsidiaries into two groups by April 2015 as part of an overall reorganization of its global production. Report

> GlaxoSmithKline and The Atlantic magazine launched a series of panel discussions on community health in Philadelphia. Report

Medical Device News

 @FierceMedDev: Terumo renewed its license of some crucial stent tech from Biosensors International. More | Follow @FierceMedDev

 @MarkHFierce: An FDA panel supports approval for Second Sight's retinal prosthesis. More | Follow @MarkHFierce

 @DamianFierce: API producer Cedarsburg Hauser is expanding its capabilities and betting on a boom in CMO demand. More | Follow @DamianFierce

> Boston Sci gains FDA nod for much-hyped S-ICD. Story

> DNA 'nanoswitch' could support quick, point-of-care Dx. Item

> AdvaMed spotlights an industry in transition. Article

> Stryker names new leader. News

Biotech News

 @FierceBiotech: TDM-1's impressive survival rate puts Roche and Genentech on track for FDA approval. More | Follow @FierceBiotech

 @JohnCFierce: MIT finance wiz calls for $30B megafund to back next-gen cancer drugs. More | Follow @JohnCFierce

 @RyanMFierce: Amid hunt for partnerships, AstraZeneca hits the blogosphere with LabTalk. More | Follow @RyanMFierce

> Ariad grabs spotlight at ESMO with 'compelling' results for lung cancer drug. Article

> Bayer, Evotec join forces on $765M endometriosis drug partnership. Item

> MIT financial wiz calls for $30B megafund to back next-gen cancer drugs. Story

CRO News

> Quintiles considering small acquisitions, CEO says. News

> FDA taps CRO Vince & Associates for $5M bioequivalent contract. Story

> FDA now in charge of clinical trial transparency. Article

> Cedarburg Hauser bets on API boom with plant expansion. Item

Biotech IT News

> AstraZeneca hits the blogosphere with LabTalk. Story

> Genomics outfit puts genetic tests on computers. News

> ChemAxon opens shop in 'heart' of Boston biotech hub. Article

> Medidata advances clinical trials software use in Japan. Item

And Finally... Former Johnson & Johnson ($JNJ) executive James E. Burke, CEO during the Tylenol scandal, died at the age of 87. Report

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.